Reevaluating the FDA's warning against the use of probiotics in preterm neonates: A societal statement by ESPGHAN and EFCNI

Chris H. P. van den Akker; Nicholas D. Embleton; Alexandre Lapillonne; Walter A. Mihatsch; Silva Salvatore; Roberto B. Canani; Ener C. Dinleyici; Magnus Domellof; Alfredo Guarino; Pedro Gutierrez-Castrellon; Iva Hojsak; Flavia Indrio; Alexis Mosca; Rok Orel; Johannes (Hans) B. van Goudoever; Zvi Weizman; Silke Mader; Luc J. I. Zimmermann; Raanan Shamir; Yvan Vandenplas; Hania Szajewska

doi:10.1002/jpn3.12204

Reevaluating the FDA's warning against the use of probiotics in preterm neonates: A societal statement by ESPGHAN and EFCNI

Chris H. P. van den Akker^*, Nicholas D. Embleton, Alexandre Lapillonne, Walter A. Mihatsch, Silva Salvatore, Roberto B. Canani, Ener C. Dinleyici, Magnus Domellof, Alfredo Guarino, Pedro Gutierrez-Castrellon, Iva Hojsak, Flavia Indrio, Alexis Mosca, Rok Orel, Johannes (Hans) B. van Goudoever, Zvi Weizman, Silke Mader, Luc J. I. Zimmermann, Raanan Shamir, Yvan VandenplasHania Szajewska

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The recent advisory issued by the United States Food and Drug Administration, cautioning against the routine administration of probiotics in preterm neonates, has sparked a lively debate within the scientific community. This commentary presents a perspective from members of the Special Interest Group on Gut Microbiota and Modifications within the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and other authors who contributed to the ESPGHAN position paper on probiotics for preterm infants, as well as representatives from the European Foundation for the Care of Newborn Infants. We advocate for a more nuanced and supportive approach to the use of certain probiotics in this vulnerable population, balancing the demonstrated benefits and risks.

Original language	English
Number of pages	6
Journal	Journal of Pediatric Gastroenterology and Nutrition
DOIs	https://doi.org/10.1002/jpn3.12204
Publication status	E-pub ahead of print - 1 Apr 2024

Keywords

live biotherapeutic product
necrotizing enterocolitis
premature infants
probiotic drug
probiotic sepsis
POSITION PAPER
WORKING GROUP
INFANTS

Access to Document

10.1002/jpn3.12204Licence: CC BY-NC-ND

Cite this

van den Akker, C. H. P., Embleton, N. D., Lapillonne, A., Mihatsch, W. A., Salvatore, S., Canani, R. B., Dinleyici, E. C., Domellof, M., Guarino, A., Gutierrez-Castrellon, P., Hojsak, I., Indrio, F., Mosca, A., Orel, R., van Goudoever, J. B., Weizman, Z., Mader, S., Zimmermann, L. J. I., Shamir, R., ... Szajewska, H. (2024). Reevaluating the FDA's warning against the use of probiotics in preterm neonates: A societal statement by ESPGHAN and EFCNI. Journal of Pediatric Gastroenterology and Nutrition. Advance online publication. https://doi.org/10.1002/jpn3.12204

@article{d37779c92c604c3a9a80979e5aa0b2d6,

title = "Reevaluating the FDA's warning against the use of probiotics in preterm neonates: A societal statement by ESPGHAN and EFCNI",

abstract = "The recent advisory issued by the United States Food and Drug Administration, cautioning against the routine administration of probiotics in preterm neonates, has sparked a lively debate within the scientific community. This commentary presents a perspective from members of the Special Interest Group on Gut Microbiota and Modifications within the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and other authors who contributed to the ESPGHAN position paper on probiotics for preterm infants, as well as representatives from the European Foundation for the Care of Newborn Infants. We advocate for a more nuanced and supportive approach to the use of certain probiotics in this vulnerable population, balancing the demonstrated benefits and risks.",

keywords = "live biotherapeutic product, necrotizing enterocolitis, premature infants, probiotic drug, probiotic sepsis, POSITION PAPER, WORKING GROUP, INFANTS",

author = "{van den Akker}, {Chris H. P.} and Embleton, {Nicholas D.} and Alexandre Lapillonne and Mihatsch, {Walter A.} and Silva Salvatore and Canani, {Roberto B.} and Dinleyici, {Ener C.} and Magnus Domellof and Alfredo Guarino and Pedro Gutierrez-Castrellon and Iva Hojsak and Flavia Indrio and Alexis Mosca and Rok Orel and {van Goudoever}, {Johannes (Hans) B.} and Zvi Weizman and Silke Mader and Zimmermann, {Luc J. I.} and Raanan Shamir and Yvan Vandenplas and Hania Szajewska",

year = "2024",

month = apr,

day = "1",

doi = "10.1002/jpn3.12204",

language = "English",

journal = "Journal of Pediatric Gastroenterology and Nutrition",

issn = "0277-2116",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

}

van den Akker, CHP, Embleton, ND, Lapillonne, A, Mihatsch, WA, Salvatore, S, Canani, RB, Dinleyici, EC, Domellof, M, Guarino, A, Gutierrez-Castrellon, P, Hojsak, I, Indrio, F, Mosca, A, Orel, R, van Goudoever, JB, Weizman, Z, Mader, S, Zimmermann, LJI, Shamir, R, Vandenplas, Y & Szajewska, H 2024, 'Reevaluating the FDA's warning against the use of probiotics in preterm neonates: A societal statement by ESPGHAN and EFCNI', Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12204

TY - JOUR

T1 - Reevaluating the FDA's warning against the use of probiotics in preterm neonates

T2 - A societal statement by ESPGHAN and EFCNI

AU - van den Akker, Chris H. P.

AU - Embleton, Nicholas D.

AU - Lapillonne, Alexandre

AU - Mihatsch, Walter A.

AU - Salvatore, Silva

AU - Canani, Roberto B.

AU - Dinleyici, Ener C.

AU - Domellof, Magnus

AU - Guarino, Alfredo

AU - Gutierrez-Castrellon, Pedro

AU - Hojsak, Iva

AU - Indrio, Flavia

AU - Mosca, Alexis

AU - Orel, Rok

AU - van Goudoever, Johannes (Hans) B.

AU - Weizman, Zvi

AU - Mader, Silke

AU - Zimmermann, Luc J. I.

AU - Shamir, Raanan

AU - Vandenplas, Yvan

AU - Szajewska, Hania

PY - 2024/4/1

Y1 - 2024/4/1

N2 - The recent advisory issued by the United States Food and Drug Administration, cautioning against the routine administration of probiotics in preterm neonates, has sparked a lively debate within the scientific community. This commentary presents a perspective from members of the Special Interest Group on Gut Microbiota and Modifications within the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and other authors who contributed to the ESPGHAN position paper on probiotics for preterm infants, as well as representatives from the European Foundation for the Care of Newborn Infants. We advocate for a more nuanced and supportive approach to the use of certain probiotics in this vulnerable population, balancing the demonstrated benefits and risks.

AB - The recent advisory issued by the United States Food and Drug Administration, cautioning against the routine administration of probiotics in preterm neonates, has sparked a lively debate within the scientific community. This commentary presents a perspective from members of the Special Interest Group on Gut Microbiota and Modifications within the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and other authors who contributed to the ESPGHAN position paper on probiotics for preterm infants, as well as representatives from the European Foundation for the Care of Newborn Infants. We advocate for a more nuanced and supportive approach to the use of certain probiotics in this vulnerable population, balancing the demonstrated benefits and risks.

KW - live biotherapeutic product

KW - necrotizing enterocolitis

KW - premature infants

KW - probiotic drug

KW - probiotic sepsis

KW - POSITION PAPER

KW - WORKING GROUP

KW - INFANTS

U2 - 10.1002/jpn3.12204

DO - 10.1002/jpn3.12204

M3 - Article

SN - 0277-2116

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

ER -